Treatment of symptoms in multiple sclerosis

Neurological Research

Volumn 28, Issue 3, 2006, Pages 306-315

  Schwendimann, Robert N ^a  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

Author keywords

Fatigue; Multiple sclerosis; Symptom; Treatment

Indexed keywords

4 AMINOPYRIDINE; AMANTADINE; AMPHETAMINE DERIVATIVE; BACLOFEN; BOTULINUM TOXIN; CANNABIDIOL; CANNABIS DERIVATIVE; CLONAZEPAM; DANTROLENE; DIAZEPAM; DOPAMINE RECEPTOR AFFECTING AGENT; DRONABINOL; GABAPENTIN; GLATIRAMER; IMIPRAMINE; IMMUNOMODULATING AGENT; LEVACECARNINE; METHYLPHENIDATE; MISOPROSTOL; MODAFINIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; ONDANSETRON; OXYBUTYNIN; PEMOLINE; PRAZEPAM; PROPIVERINE; PROSTAGLANDIN E1; THREONINE; TIZANIDINE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG; VIGABATRIN;

ANKLE EDEMA; ANXIETY DISORDER; BALANCE DISORDER; BLADDER DYSFUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DELIRIUM; DIARRHEA; DISABILITY; DISEASE COURSE; DIZZINESS; DRUG DEPENDENCE; DRUG EFFICACY; DYSARTHRIA; DYSPEPSIA; FATIGUE; FLUID RETENTION; GAIT DISORDER; HAIR DISEASE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVEDO RETICULARIS; LIVER TOXICITY; LOOSE FECES; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NEUROIMAGING; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PAIN; PALLIATIVE THERAPY; PARESTHESIA; PRIAPISM; PSYCHOSIS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SPASTICITY; SYMPTOMATOLOGY; TREMOR; URINE RETENTION; WEAKNESS; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

COGNITION DISORDERS; DEPRESSION; DISABILITY EVALUATION; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; PAIN; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREMA; URINARY BLADDER DISEASES; VERTIGO;

EID: 33646790123     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164106X98206     Document Type: Review

References (65)

1. Crayton H, Heyman RA, Rossman HS. A multimodal approach to managing the symptoms of multiple sclerosis. Neurology 2004; 63 (11 Suppl. 5): S12-S18
2. Tullman M. Symptomatic therapy in multiple sclerosis. Continuum 2004; 10: 142-172
3. Krupp LB. Fatigue in multiple sclerosis: Definition, pathophysiology and treatment. CNS Drugs 2003; 17: 225-234
4. Clanet MG, Brassat D. The management of multiple sclerosis patients. Curr Opin Neurol 2003; 13: 265-270
5. Petajan JH, Gappmaier E, White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996; 39: 432-441
6. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004; 62: 2058-2064
7. Beenakker E, Oparina T, Hartgring A, et al. Cooling garment treatment in MS: Clinical improvement and decrease in leukocyte no production. Neurology 2001; 57: 892-894
8. Schwid SR, Petrie MD, Murray R, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for multiple sclerosis. Neurology 2003; 60: 1955-1960
9. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group. Can J Neurol Sci 1987; 14: 273-278
10. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676-680
11. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: Results of a double-blind, randomized, parallel trial of amantadine, pemoline and placebo. Neurology 1995; 45: 1956-1961
12. Taus C, Giuliani G, Pucci E, et al. Amantadine in multiple sclerosis. Cochrane Database Syst Rev 2003; (2): CD002818
13. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002; 72: 179-183
14. Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002; 249: 983-987
15. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000; 20: 8620-8628
16. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study. Neurology 2005; 64: 1139-1143
17. Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-1471
18. Berkovitch M, Pope E, Phillips J, et al. Pemoline-associated fulminant liver failure: Testing the evidence for causation. Clin Pharmacol Ther 1995; 57: 696-698
19. Polman CH, Bertelsmann FW, van Loenen AC, et al. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994; 51: 292-296
20. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: Results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001; 7: 354-358
21. Bever CT, Jr, Anderson PA, Leslie J, et al. Treatment with 3,4 diaminopyridine in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996; 47: 1457-1462
22. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomized, double-blind, crossover trial. J Neurol Sci 2004; 218: 103-108
23. Wingerchuk DM, Benarroch EE, O'Brien PC, et al. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005; 64: 1267-1269
24. Paisley S, Beard S, Hunn A, et al. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: A systematic review. Mult Scler 2002; 8: 319-329
25. Bramanti P, Sessa E, Rifici C, et al. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology 1998; 51: 1720-1723
26. Cutter NC, Scott DD, Johnson JC, et al. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Arch Phys Med Rehab 2000; 81: 164-169
27. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomized, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000; 68: 707-712
28. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004; 75: 951-957
29. Coffey RJ, Cahil D, Steers W, et al. Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenter study. J Neurosurg 1993; 78: 226-232
30. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomized placebo-controlled trial. Lancet 2003; 362: 1517-1526
31. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Syst Rev 2001; (4): CD001332
32. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: Management strategies. Drugs 2003; 63: 153-166
33. Valiquette G, Herbert J, Maede-D'Alisera P. Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol 1996; 53: 1270-1275
34. Fowler CJ. Intravesical treatment of the overactive bladder. Urology 2000; 55: 60-64
35. Fowler CJ, Beck RO, Gerrard S, et al. Intravesical capsaicin for treatment of detrusor hyperreflexia. J Neurol Neurosurg Psychiatry 1994; 57: 169-173
36. Dykstra DD, Pryor J, Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: A case report. Arch Phys Med Rehabil 2003; 84: 1399-1400
37. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-697
38. Brady CM, DasGupta R, Dalton C, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004; 10: 425-433
39. Finger WW, Lund M, Slagle MA. Medications that may contribute to sexual disorders. A Guide to assessment and treatment in family practice. J Fam Pract 1997; 44: 33-43
40. Fowler C, Miller J, Sharief M. Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis. Ann Neurol 1999; 46: 497
41. Teloken C, Rhoden EL, Sogari P, et al. Therapeutic effects of high dose yohimbine hydrochloride on organic erectile dysfunction. J Urol 1998; 159: 122-124
42. Padma-Nathan H, Hellstron WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997; 336: 1-7
43. Ganem JP, Lucey DT, Janosko EO, et al. Unusual complications of the vacuum erection device. Urology 1998; 51: 627-631
44. Lillius H, Valtonen C, Wilkstrom J. Sexual problems in patients suffering from multiple sclerosis. J Chron Dis 1976; 19: 643-647
45. Crenshaw TL, Goldberg JP, Stern WC. Pharmacologic modification of psychosexual dysfunction. J Sex Marital Ther 1987; 13: 239-252
46. Caruso S, Intelisano G, Lupo L, et al. Premenopausal women affected by sexual arousal disorder treated with sildenafil: A double-blind, cross-over, placebo-controlled study. BJOG 2001; 108: 623-628
47. Krupp LB, Rizvi SA. Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology 2002; 58 (8 Suppl. 4): S32-S39
48. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996; 46: 628-632
49. Amato MP, Zipoli V. Clinical management of cognitive impairment in multiple sclerosis: A review of current evidence. Int MS J 2003; 10: 72-83
50. Krupp LB, Christodoulou C, Melville P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63: 1579-1585
51. Alusi Sh, Worthington J, Glickman S, et al. A study of tremor in multiple sclerosis. Brain 2001; 124: 720-730
52. Fox P, Bain PG, Glickman S, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004; 62: 1105-1109
53. Wishart HA, Roberts DW, Roth RM, et al. Chronic deep brain stimulation for the treatment of tremor in multiple sclerosis: A review and case reports. J Neurol Neurosurg Psychiatry 2003; 74: 1392-1397
54. Hooper J, Whittle IR. Costs of thalamic deep brain stimulation for movement disorders in patients with multiple sclerosis. Br J Neurosurg 2003; 17: 40-45
55. Rice GP, Lesaux J, Vandervoort P, et al. Ondansetron, a 5-HT3 antagonist improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997; 62: 282-284
56. Jain S, Proudlock F, Constantinescu CS, et al. Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. Am J Ophthal 2002; 134: 780-782
57. Straube A. Pharmacology of vertigo/nystagmus/oscillopsia. Curr Opin Neurol 2005; 18: 11-14
58. Starck M, Albrecht H, Pollmann W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol 1996; 244: 9-16
59. Svendsen KB, Jansen TS, Overvad K, et al. Pain in patients with multiple sclerosis: A population based study. Arch Neurol 2003; 60: 1089-1094
60. Berk C, Constantoyannis C, Honey CR. The treatment of trigeminal neuralgia in patients with multiple sclerosis using percutaneous radiofrequency rhizotomy. Can J Neurol Sci 2003; 30: 220-223
61. Broggi G, Ferroli P, Franzini A, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery 2004; 55: 830-838
62. Rogers CL, Shetter AG, Ponce FA, et al. Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis. J Neurosurg 2002; 97: 529-532
63. Thompson AJ. Neurorehabilitation in multiple sclerosis: Foundations, facts and fiction. Curr Opin Neurol 2005; 18: 267-271
64. Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005; 4: 643-652
65. Thompson AJ. Symptomatic management and rehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 71 (Suppl. 2): ii22-ii27